As a control, we demonstrate that re-expression of ectopic wild-type KRAS* was more effective than KRAS*C118S at restoring tumor growth of oncogenic HRASG12V-transformed KrasC118S/C118S MEFs (Fig 4H). This evidence concerns the gene KRAS and neoplasm.